/1b/44/eddf194b13f3358244409958ca5e.png "HJERTEMAGNYL 150 mg/21 mg coated tablets, 100 pcs.")
Consult our pharmacist
Therapeutic indications:
Acute and chronic ischemic heart disease.
Prevention of recurrent thrombosis. Primary prevention of cardiovascular disease, including thrombosis and acute coronary events, in people over 50 years of age who have one or more of the following symptoms that may indicate an increased risk of cardiovascular disease: hypertension, hypercholesterolemia, diabetes mellitus, obesity (BMI>30) or a family history of myocardial infarction before the age of 55 in at least one parent, brother or sister.
Hjertemagnyl 150 mg/21 mg has a mild anticoagulant effect. It reduces the risk of blood platelet coagulation and blood clot formation, thereby reducing the risk of coronary heart disease, myocardial infarction and stroke.
Therapeutic indications:
Acute and chronic ischemic heart disease.
Prevention of recurrent thrombosis. Primary prevention of cardiovascular disease, including thrombosis and acute coronary events, in people over 50 years of age who have one or more of the following symptoms that may indicate an increased risk of cardiovascular disease: hypertension, hypercholesterolemia, diabetes mellitus, obesity (BMI>30) or a family history of myocardial infarction before the age of 55 in at least one parent, brother or sister.
Hjertemagnyl 150 mg/21 mg has a mild anticoagulant effect. It reduces the risk of blood platelet coagulation and blood clot formation, thereby reducing the risk of coronary heart disease, myocardial infarction and stroke.